Lépjen offline állapotba az Player FM alkalmazással!
#24 A week in the name of medicines safety – part 1
Manage episode 424661241 series 2749727
To mark #MedSafetyWeek, which takes place from 6–12 November, we’re releasing a special two-part episode on pharmacovigilance communication campaigns. In this first part, we speak to Mitul Jadeja from the Medicines and Healthcare products Regulatory Agency in the UK about under-reporting and how initiatives like #MedSafetyWeek can help draw attention to medicines safety.
Tune in to find out:
- Why under-reporting plagues all pharmacovigilance systems
- What regulators can do to encourage people to report side effects
- Why we need reports from both patients and healthcare professionals
Want to know more?
Here are the studies cited in the episode:
- A BMJ study in 2022 measured the burden and associated cost of adverse drug reactions, polypharmacy and multimorbidity at a hospital in the UK.
- In 1976, Inman proposed a theoretical model, known as the ‘seven deadly sins’, to explain why healthcare professionals fail to report adverse drug reactions. This recent systematic review in Drug Safety expands on that.
- The SCOPE Joint Action project aimed to enhance pharmacovigilance in the EU and delivered practical guidance for regulators.
- The first UK study to compare Yellow Card reports from patients and healthcare professionals was published in 2012.
To join the #MedSafetyWeek campaign next week, follow the hashtag online and check out the campaign website for free social media materials.
Finally, don’t forget to tune in on 13 November for part 2 of this podcast, where we’ll hear from #MedSafetyWeek advocates in Iraq, Luxembourg, and Namibia about their experience with the campaign. Read a preview of the conversation on Uppsala Reports.
Join the conversation on social media
Follow us on X, LinkedIn, or Facebook and share your thoughts about the show with the hashtag #DrugSafetyMatters.
Got a story to share?
We’re always looking for new content and interesting people to interview. If you have a great idea for a show, get in touch!
About UMC
Read more about Uppsala Monitoring Centre and how we work to advance medicines safety.
Fejezetek
1. #24 A week in the name of medicines safety – part 1 (00:00:00)
2. Intro (00:00:15)
3. Welcome, Mitul! (00:01:49)
4. Why we need communications campaigns (00:01:58)
5. Barriers to reporting (00:06:07)
6. Different reporters, different perspectives (00:09:45)
7. Other interventions to prompt reporting (00:14:23)
8. Global versus local (00:19:08)
9. Future of #MedSafetyWeek (00:22:55)
10. Outro (00:25:19)
51 epizódok
Manage episode 424661241 series 2749727
To mark #MedSafetyWeek, which takes place from 6–12 November, we’re releasing a special two-part episode on pharmacovigilance communication campaigns. In this first part, we speak to Mitul Jadeja from the Medicines and Healthcare products Regulatory Agency in the UK about under-reporting and how initiatives like #MedSafetyWeek can help draw attention to medicines safety.
Tune in to find out:
- Why under-reporting plagues all pharmacovigilance systems
- What regulators can do to encourage people to report side effects
- Why we need reports from both patients and healthcare professionals
Want to know more?
Here are the studies cited in the episode:
- A BMJ study in 2022 measured the burden and associated cost of adverse drug reactions, polypharmacy and multimorbidity at a hospital in the UK.
- In 1976, Inman proposed a theoretical model, known as the ‘seven deadly sins’, to explain why healthcare professionals fail to report adverse drug reactions. This recent systematic review in Drug Safety expands on that.
- The SCOPE Joint Action project aimed to enhance pharmacovigilance in the EU and delivered practical guidance for regulators.
- The first UK study to compare Yellow Card reports from patients and healthcare professionals was published in 2012.
To join the #MedSafetyWeek campaign next week, follow the hashtag online and check out the campaign website for free social media materials.
Finally, don’t forget to tune in on 13 November for part 2 of this podcast, where we’ll hear from #MedSafetyWeek advocates in Iraq, Luxembourg, and Namibia about their experience with the campaign. Read a preview of the conversation on Uppsala Reports.
Join the conversation on social media
Follow us on X, LinkedIn, or Facebook and share your thoughts about the show with the hashtag #DrugSafetyMatters.
Got a story to share?
We’re always looking for new content and interesting people to interview. If you have a great idea for a show, get in touch!
About UMC
Read more about Uppsala Monitoring Centre and how we work to advance medicines safety.
Fejezetek
1. #24 A week in the name of medicines safety – part 1 (00:00:00)
2. Intro (00:00:15)
3. Welcome, Mitul! (00:01:49)
4. Why we need communications campaigns (00:01:58)
5. Barriers to reporting (00:06:07)
6. Different reporters, different perspectives (00:09:45)
7. Other interventions to prompt reporting (00:14:23)
8. Global versus local (00:19:08)
9. Future of #MedSafetyWeek (00:22:55)
10. Outro (00:25:19)
51 epizódok
Minden epizód
×Üdvözlünk a Player FM-nél!
A Player FM lejátszó az internetet böngészi a kiváló minőségű podcastok után, hogy ön élvezhesse azokat. Ez a legjobb podcast-alkalmazás, Androidon, iPhone-on és a weben is működik. Jelentkezzen be az feliratkozások szinkronizálásához az eszközök között.